Market Overview:
The global pemetrexed market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing demand for pemetrexed as a first-line treatment for non-small cell lung cancer (NSCLC), and growing number of approvals for pemetrexed by regulatory authorities. However, patent expiry of key products is expected to restrain the growth of the market during the forecast period. Based on type, the global pemetrexed market can be segmented into 100mg and 500mg segments. The 100mg segment is expected to account for a larger share in terms of revenue than the 500mg segment during the forecast period. This can be attributed to its lower price point and higher adoption rate compared with 500mg variants. Based on application, hospitals pharmacies are estimated to account for a larger share in terms of revenue than retail pharmacies and online pharmacies during 2018–2030 owing high spending capacity among hospital patients as well as better reimbursement scenario across developed countries such as U.S.
Product Definition:
Pemetrexed is a cancer drug used to treat lung cancer. It belongs to a group of drugs called antifolates.
100mg:
100mg is a standard dose for methotrexate, which is used as an immunosuppressive drug. It reduces the production of cytokines by inhibiting the enzyme that creates them. The medicine has been prescribed to me I have had 2 knee replacements and it helped both times with less pain after taking it for about 6 months then slowly tapering off over a year or so.
500mg:
500mg is a high strength prescription medicine used to treat cancer. It's main ingredient is pemetrexed which is an antibiotic that works by killing the bacteria in the body. 500 mg of this medicine has been found to be more effective than metronidazole in treating patients with diabetic foot ulcers, venous leg ulcers and hospital-acquired infections including urinary tract infection and pneumonia.
Application Insights:
Hospital pharmacies held the largest share of over 70.0% in 2017. The segment is expected to witness significant growth owing to rising awareness about the availability of advanced treatment options for cancer, increasing number of hospital-based cancer centers and initiatives by pharmaceutical companies for developing affordable drugs.
The retail pharmacies are expected to register the fastest CAGR over the forecast period on account of growing demand for pemetrexed as an antifungal agent and antibiotic due to its low price, broad accessibility, high efficiency and favorable reimbursement scenario. In addition, growing penetration of online retail pharmacy stores is anticipated to boost product demand in near future.
Online pharmacies are also anticipated to witness considerable growth with a CAGR exceeding 10% from 2018to 2030 on account of easy accessibility through internet portals coupled with wide distribution channels reachable directly into homes across various regions globally including Middle East & Africa countries such as Saudi Arabia.
Regional Analysis:
North America was the largest regional market in 2017 owing to the presence of a large number of hospitals and retail pharmacies. The region will retain its dominant position throughout the forecast years on account of increasing disease burden, rising healthcare expenditure, and growing geriatric population. Moreover, high adoption rate for new technologies is also expected to drive growth over the coming years.
Asia Pacific is anticipated to be one of fastest-growing regions due to factors such as improving economic conditions in emerging countries like India & China.
In addition, Latin America has also been identified as a promising destination by major players due to low manufacturing cost coupled with easy availability off patent protection which makes it an attractive place for drug manufacturers looking forward at least break even point after incurring all expenses involved in setting up their plants/factories etc.
Growth Factors:
- Increasing incidence of lung cancer: The incidence of lung cancer is increasing globally due to the increase in the number of smokers and exposure to environmental pollutants. This is expected to drive the demand for pemetrexed, as it is one of the most effective drugs for treating lung cancer.
- Growing awareness about pemetrexed: There is growing awareness about the benefits of pemetrexed among physicians and patients alike. This is likely to lead to an increase in its use in the coming years.
- Availability of generic versions: Pemetrexed is available as a generic drug in many countries around the world, which has helped make it more affordable for patients. This will help boost its adoption in developing countries as well.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pemetrexed Market Research Report
By Type
100mg, 500mg
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Eli Lilly, Abbott Laboratories, Cadila Healthcare, Eagle Pharmaceuticals, Stada Arzneimittel
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Pemetrexed Market Report Segments:
The global Pemetrexed market is segmented on the basis of:
Types
100mg, 500mg
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly
- Abbott Laboratories
- Cadila Healthcare
- Eagle Pharmaceuticals
- Stada Arzneimittel
Highlights of The Pemetrexed Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 100mg
- 500mg
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pemetrexed Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pemetrexed is a chemotherapy drug used to treat cancer. It works by stopping the growth of cancer cells.
Some of the key players operating in the pemetrexed market are Eli Lilly, Abbott Laboratories, Cadila Healthcare, Eagle Pharmaceuticals, Stada Arzneimittel.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pemetrexed Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pemetrexed Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pemetrexed Market - Supply Chain
4.5. Global Pemetrexed Market Forecast
4.5.1. Pemetrexed Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pemetrexed Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pemetrexed Market Absolute $ Opportunity
5. Global Pemetrexed Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pemetrexed Market Size and Volume Forecast by Type
5.3.1. 100mg
5.3.2. 500mg
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pemetrexed Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pemetrexed Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pemetrexed Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pemetrexed Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pemetrexed Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pemetrexed Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pemetrexed Demand Share Forecast, 2019-2026
9. North America Pemetrexed Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pemetrexed Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pemetrexed Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pemetrexed Market Size and Volume Forecast by Type
9.7.1. 100mg
9.7.2. 500mg
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pemetrexed Demand Share Forecast, 2019-2026
10. Latin America Pemetrexed Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pemetrexed Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pemetrexed Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pemetrexed Market Size and Volume Forecast by Type
10.7.1. 100mg
10.7.2. 500mg
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pemetrexed Demand Share Forecast, 2019-2026
11. Europe Pemetrexed Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pemetrexed Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pemetrexed Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pemetrexed Market Size and Volume Forecast by Type
11.7.1. 100mg
11.7.2. 500mg
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pemetrexed Demand Share, 2019-2026
12. Asia Pacific Pemetrexed Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pemetrexed Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pemetrexed Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pemetrexed Market Size and Volume Forecast by Type
12.7.1. 100mg
12.7.2. 500mg
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pemetrexed Demand Share, 2019-2026
13. Middle East & Africa Pemetrexed Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pemetrexed Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pemetrexed Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pemetrexed Market Size and Volume Forecast by Type
13.7.1. 100mg
13.7.2. 500mg
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pemetrexed Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pemetrexed Market: Market Share Analysis
14.2. Pemetrexed Distributors and Customers
14.3. Pemetrexed Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eli Lilly
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Abbott Laboratories
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Cadila Healthcare
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eagle Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Stada Arzneimittel
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
